Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474903 · ClinicalTrials.gov registry record · Phase 2
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00474903: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00474903 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00474903, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying the effect of esomeprazole magnesium and aspirin on tissue PGE2 levels compared with esomeprazole and placebo. This type of chemoprevention treatment investigates the use of certain drugs to assess whether they assist in the prevention of cancer. The use of esomeprazole magnesium with or without aspirin may help prevent esophageal cancer in patients with Barrett esophagus.
Interventions
- OTHER placebo
- DRUG acetylsalicylic acid
- DRUG esomeprazole magnesium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474903
The ClinicalTrials.gov registry entry for NCT00474903 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00474903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00474903 about?
NCT00474903 is a clinical study titled "Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus". This randomized phase II trial is studying the effect of esomeprazole magnesium and aspirin on tissue PGE2 levels compared with esomeprazole and placebo. This type of chemoprevention treatment investigates the use of certain drugs to assess whether they assist in the prevention of cancer. The use of...
What is the current status of trial NCT00474903?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2007-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00474903?
The interventions under investigation include: placebo (OTHER), acetylsalicylic acid (DRUG), esomeprazole magnesium (DRUG).
Who is sponsoring clinical trial NCT00474903?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.